BOSTON– SmartLabs, a Boston-based Laboratory-as-a-Service (LaaS) leader, today announced the tripling of its footprint on the West Coast with the opening of the world’s largest multi-modality and multi-product cGMP center for cell and gene therapies. Following the recent opening of its newest East Coast location in 2021, SmartLabs continues its accelerated growth with a plan to scale operations to 2 million square feet within five years.
Located in the heart of the South San Francisco biotech corridor, SmartLabs’ latest research center supports end-to-end drug development, including benchtop to 500L manufacturing that supports multiple modalities, including allogenic and autologous cell therapies.
“Launching the world’s largest multi-modality and multi-product cGMP center for cell and gene therapies is yet another validation of SmartLabs’ leadership in innovative lab design. By transforming the traditional approach to biotech lab outsourcing and infrastructure, we have been able to offer our global outsourcing platform which incorporates advanced scientific infrastructure and resources for companies of all sizes and approaches,” said Amrit Chaudhuri, CEO and co-founder of SmartLabs.
“Our city, as the birthplace of biotech, is the perfect location for SmartLabs to launch their new offering,” said Mayor Mark Nagales. “South San Francisco’s biotech ecosystem is brimming with talent and innovation, and by tripling their footprint in the area, SmartLabs is making end-to-end drug development opportunities available in our own backyard. The convenience and expertise of the SmartLabs offering will undoubtedly help local companies rapidly advance their science.”
“I’m thrilled that SmartLabs has decided to expand in my district, which will build on South San Francisco’s legacy of innovation, reputation for world-class talent, and commitment to improving human health,” said U.S. Rep. Jackie Speier.
“We are excited to welcome SmartLabs to the Gateway of Pacific campus – the front door to South San Francisco,” said Scott Altick, Vice President of Leasing. “BioMed’s 16 million square feet of options allow tenants, like SmartLabs, to grow their business and expand easily between properties. Gateway of Pacific is the third location for SmartLabs’ advanced resourcing in our portfolio and they will be a fantastic addition to our campus and the larger South San Francisco biotech cluster.”
750 Gateway offers 28 product suites of state-of-the-art cGMP manufacturing in ISO 5 and ISO 7 clean room environments. This is the third SmartLabs site capable of end-to-end drug development with cGMP/pilot-scale for SmartLabs clients and the sixth site overall.
“Catalyst Biosciences partnering with SmartLabs’ flexible infrastructure solution has accelerated our program goals and has enabled us to maintain control over each step of the R&D process,” said Tim Myles, Director Protein Engineering at Catalyst Biosciences, “The SmartLabs team are professional and reactive to our needs which allows us to focus on the science. Access to advanced cGMP capacities on flexible terms will be revolutionary for progressing Catalyst Biosciences breakthrough protease therapeutics for complement related diseases.”
In addition to cGMP, 750 Gateway also offers private innovation suites, corporate R&D suites, in vivo research suites, and process development suites. With this launch, SmartLabs has opened the largest footprint of end-to-end enterprise grade pharma resourcing. SmartLabs runs off SmartLabs v.4.0 OS and the most advanced, tech-forward building technology.
Capacities are already being negotiated for the initial cohort of clients starting in Q4 2022.
